Affordable Access

Publisher Website

Lymphoblastoid alpha-interferon weekly, daily and combined with acyclovir for chronic HBeAg-positive hepatitis

Elsevier B.V.
Publication Date
DOI: 10.1016/s0168-8278(86)80119-2
  • Session F: Clinical Trials Of The Interferons
  • Medicine


Summary Patients with chronic hepatitis B and active viral replication had no change in DNA-polymerase (DNA-p) and HBeAg when treated with weekly injections of lymphoblastoid alpha-interferon (IFN) for 4–10 weeks. Daily IFN (2.5 MU/m 2 for a period of 4 weeks) was associated with a significant fall ( P < 0.05) in DNA-p but not in HBeAg; DNA-p remained or became negative in 3 out of 10 patients after stopping therapy. Combination of IFN and intravenous acyclovir (ACV, 15 mg/kg twice daily) led to a significantly greater fall in DNA-p and HBeAg, while tolerance of the combination therapy was excellent. Four out of 5 patients became DNA-p-negative and three HBeAg-negative; subsequently two became HBsAg-negative with anti-HBs. We conclude that weekly IFN appears ineffective. Daily IFN depressed hepatitis B virus replication, but does not change markedly the natural course of the disease. Combination therapy with ACV may be more effective than IFN alone and is well tolerated.

There are no comments yet on this publication. Be the first to share your thoughts.